Asterias Biotherapeutics, Inc will present new 9 -
month efficacy and safety data from their ongoing Phase I / IIa trial for OPC - 1 in a workshop and poster presentation.
At the International Society for Stem Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 -
month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor cells.
Not exact matches
With the initial contract of $ 24.9 million over the next 18
months, Mapp Pharmaceutical will manufacture a small amount of the drug for early - stage clinical studies to demonstrate its
safety and efficacy in people.
Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering
and developing innovative gene therapies for retinal neurodegenerative diseases
and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the
safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6
and 12
months prior to study treatment.
METHODS: Three hundred seventy - two patients with mild to moderate AD were randomized to receive IM injections of AN1792 or placebo (4:1) at baseline
and at
months 1, 3, 6, 9,
and 12 in a multicenter Phase II
safety, tolerability,
and pilot
efficacy study.
The study, named FIREFISH, will investigate the
safety, tolerability
and efficacy of RG7916 in babies aged 1 to 7
months.
However, the
safety and efficacy in pediatric patients less than 12
months of age has not been established.
Simparica underwent extensive field
safety and efficacy testing involving more than 900 dogs over a two - or three -
month period.
Studies to establish the
safety and efficacy of Clomicalm Tablets in dogs less than 6
months of age have not been conducted.
The
safety and efficacy of Clomicalm Tablets have not been established in dogs less than 6
months of age or in pregnant or lactating female dogs.